Literature DB >> 9215527

Studies on the function of rho A protein in cardiac myofibrillogenesis.

S M Wang1, Y J Tsai, M J Jiang, Y Z Tseng.   

Abstract

The aim of this study was to provide morphological evidence for the presence of rho A protein in developing cardiomyocytes and to investigate its possible role in myofibrillogenesis. Immunostaining with a monoclonal anti-rho antibody gave a diffuse pattern in the cytosol of cultured cardiomyocytes. Introduction of C3 exoenzyme into the cells by electroporation was used to inactivate rho A protein by ADP-ribosylation. An immunostaining with anti-vinculin, anti-talin, and anti-integrin antibodies showed the focal adhesions in electroporation control cardiomyocytes to be evenly distributed in the ventral sarcolemma; the costameric structure was also detected using these antibodies. In contrast, in C3 exoenzyme treated cells, focal adhesions were disassembled and costamere were absent; in addition, beta-actin-positive, non-striated fibrils were lost and assembly of M-protein, titin, and alpha-actinin into myofibrils was poor, as shown by diffuse and filamentous staining pattern. C3 exoenzyme treatment had a less marked effect on mature cardiomyocytes than on immature cells; in this case, cells became distorted and few myofibrils were seen. The intensity of anti-phosphotyrosine antibody staining of the focal adhesion was also decreased or diffuse in C3 exoenzyme-treated cardiomyocytes, suggesting dephosphorylation of focal adhesion components. We therefore conclude that small G protein rho A plays an important role in myofibril assembly in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215527

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

Review 1.  Pleiotropic effects of statins.

Authors:  James K Liao; Ulrich Laufs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

2.  Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1.

Authors:  M A Sussman; S Welch; A Walker; R Klevitsky; T E Hewett; R L Price; E Schaefer; K Yager
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 3.  Statins and the myocardium.

Authors:  Seema Mital; James K Liao
Journal:  Semin Vasc Med       Date:  2004-11

Review 4.  Mechanical stress-induced sarcomere assembly for cardiac muscle growth in length and width.

Authors:  Brenda Russell; Matthew W Curtis; Yevgeniya E Koshman; Allen M Samarel
Journal:  J Mol Cell Cardiol       Date:  2010-02-24       Impact factor: 5.000

5.  Distinct roles for the N- and C-terminal regions in the cytotoxicity of pierisin-1, a putative ADP-ribosylating toxin from cabbage butterfly, against mammalian cells.

Authors:  T Kanazawa; M Watanabe; Y Matsushima-Hibiya; T Kono; N Tanaka; K Koyama; T Sugimura; K Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 6.  Statin therapy for cardiac hypertrophy and heart failure.

Authors:  James K Liao
Journal:  J Investig Med       Date:  2004-05       Impact factor: 2.895

7.  Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure.

Authors:  V P Sah; S Minamisawa; S P Tam; T H Wu; G W Dorn; J Ross; K R Chien; J H Brown
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 8.  A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms.

Authors:  Hironori Nakagami; Kristin S Jensen; James K Liao
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

Review 9.  Statins and myocardial hypertrophy.

Authors:  Hironori Nakagami; James K Liao
Journal:  Coron Artery Dis       Date:  2004-08       Impact factor: 1.439

Review 10.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.